Cargando…

Preclinical pharmacodynamic evaluation of drug candidate SKLB-178 in the treatment of non-small cell lung cancer

Non-small cell lung cancer (NSCLC) is a serious life-threatening malignancy. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, such as Gefitinib and Erlotinib, are effective clinical medicines for advanced NSCLC patients harboring EGFR-activating mutations. However, this therapy ju...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhong, Lei, Yang, Jiao, Cao, Zhixing, Chen, Xin, Hu, Yiguo, Li, Linli, Yang, Shengyong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355060/ https://www.ncbi.nlm.nih.gov/pubmed/28086226 http://dx.doi.org/10.18632/oncotarget.14597

Ejemplares similares

SKLB188 inhibits the growth of head and neck squamous cell carcinoma by suppressing EGFR signalling
por: Barzegar, Mansoureh, et al.
Publicado: (2017)

Preclinical pharmacodynamic evaluation of a new Src/FOSL1 inhibitor, LY‐1816, in pancreatic ductal adenocarcinoma
por: Yang, Wei, et al.
Publicado: (2019)

Pharmacodynamic assays to facilitate preclinical and clinical development of pre-mRNA splicing modulatory drug candidates
por: Shi, Yihui, et al.
Publicado: (2015)

Preclinical pharmacodynamic evaluation of antibiotic nitroxoline for anticancer drug repurposing
por: ZHANG, QI, et al.
Publicado: (2016)

Symphonies Wq 178, 174, 175, 178, 180
por: Bach, Carl Philipp Emanuel, 1714-1788
Publicado: (1997)

SKLB-677, an FLT3 and Wnt/β-catenin signaling inhibitor, displays potent activity in models of FLT3-driven AML
por: Ma, Shuang, et al.
Publicado: (2015)

SKLB023 as an iNOS inhibitor alleviated liver fibrosis by inhibiting the TGF-beta/Smad signaling pathway
por: Zhang, Jinhang, et al.
Publicado: (2018)

Transport and pharmacodynamics of albitiazolium, an antimalarial drug candidate
por: Wein, S, et al.
Publicado: (2012)

Protective effects of SKLB023 on a mouse model of unilateral ureteral obstruction by the modulation of gut microbiota
por: Feng, Yanhuan, et al.
Publicado: (2018)

A novel multikinase inhibitor SKLB‐YTH‐60 ameliorates inflammation and fibrosis in bleomycin‐induced lung fibrosis mouse models
por: Liu, Hongyao, et al.
Publicado: (2021)

P1009: SKLB054, A NOVEL JAK2 INHIBITOR, POTENTLY TREATS MYELOPROLIFERATIVE NEOPLASM WITH JAK2V617F MUTATION
por: Zhao, Ailin, et al.
Publicado: (2023)

SKLB1002, a potent inhibitor of VEGF receptor 2 signaling, inhibits endothelial angiogenic function in vitro and ocular angiogenesis in vivo
por: Zhang, Qiu-Yang, et al.
Publicado: (2020)

Decay spectroscopy of $^{178}$Au
por: Whitmore, B
Publicado: (2015)

Memorandum: proposal P 178
por: Vannucci, François
Publicado: (1984)

Lifetime Measurements in (178)Hf
por: de Haan, R. C., et al.
Publicado: (2000)

SKLB023 protects mice against acute liver injury by inhibiting proinflammatory cytokine production in both T cells and macrophages
por: Yu, Jia, et al.
Publicado: (2018)

SKLB023 hinders renal interstitial fibrosis in obstructive nephropathy by interfering TGF-β1/Smad3 signaling
por: Feng, Yanhuan, et al.
Publicado: (2018)

Preclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric  Oxyhydroxide
por: Cozzolino, Mario, et al.
Publicado: (2014)

Mixed micelles loaded with the 5-benzylidenethiazolidine-2,4-dione derivative SKLB023 for efficient treatment of non-alcoholic steatohepatitis
por: Li, Yanping, et al.
Publicado: (2019)

S178. ALTERED GYRIFICATION IN THE SCHIZOPHRENIA SPECTRUM
por: Sasabayashi, Daiki, et al.
Publicado: (2018)

Health Tract, No. 178: Weather Signs
Publicado: (1863)

Health Tract, No. 178: Weather Signs
Publicado: (1865)

SKLB-163, a new benzothiazole-2-thiol derivative, exhibits potent anticancer activity by affecting RhoGDI/JNK-1 signaling pathway
por: Peng, X, et al.
Publicado: (2014)

SKLB023 Blocks Joint Inflammation and Cartilage Destruction in Arthritis Models via Suppression of Nuclear Factor-Kappa B Activation in Macrophage
por: Xie, Caifeng, et al.
Publicado: (2013)

Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine
por: Kiss, Béla, et al.
Publicado: (2019)

The alpha decay of $^{179}$Hg and $^{178}$Hg
por: Hansen, P G, et al.
Publicado: (1971)

The alpha decay of $^{179}Hg$ and $ ^{178}Hg$
por: Hansen, P G, et al.
Publicado: (1971)

Memorandum: space and time for exp PS 178
por: Bressani, Tullio
Publicado: (1984)

Author index of volume 178 Supplement 1
Publicado: (2006)

Nonsurgical Treatment for Vocal Fold Leukoplakia: An Analysis of 178 Cases
por: Chen, Min, et al.
Publicado: (2017)

Identification of key candidate genes and small molecule drugs in cervical cancer by bioinformatics strategy
por: Tang, Xin, et al.
Publicado: (2018)

Transplanted organoids empower human preclinical assessment of drug candidate for the clinic
por: Westerling-Bui, Amy D., et al.
Publicado: (2022)

Magnetic resonance imaging of RRx-001 pharmacodynamics in preclinical tumors
por: Raghunand, Natarajan, et al.
Publicado: (2017)

A novel orally available Syk/Src/Jak2 inhibitor, SKLB-850, showed potent anti-tumor activities in B cell lymphoma (BCL) models
por: Zhang, Nannan, et al.
Publicado: (2017)

Novel preclinical models of topical PrEP pharmacodynamics provide rationale for combination of drugs with complementary properties
por: Mesquita, Pedro MM, et al.
Publicado: (2013)

A model-informed preclinical approach for prediction of clinical pharmacodynamic interactions of anti-TB drug combinations
por: Clewe, Oskar, et al.
Publicado: (2018)

Preclinical pharmacokinetics and pharmacodynamics of DCLL9718A: An antibody-drug conjugate for the treatment of acute myeloid leukemia
por: Leipold, Douglas D., et al.
Publicado: (2018)

$\alpha$-decay and $\beta$-delayed fission of $^{178}$TI
por: Liberati, V
Publicado: (2015)

HOM Load for the Single-mode 178 MHz Cavity
por: Volkov, V, et al.
Publicado: (2002)

T178. MICROPIPETTE-GUIDED DRUG ADMINISTRATION (MDA) METHOD AS A NOVEL PHARMACOLOGICAL TREATMENT METHOD IN MICE: PRECLINICAL VALIDATION USING RISPERIDONE IN THE MATERNAL IMMUNE ACTIVATION MODEL OF NEURODEVELOPMENTAL DISORDERS
por: Scarborough, Joseph, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_eaqa0ob0h1tjtp5dh1u2hjgesk